US Bancorp DE Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

US Bancorp DE raised its stake in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,522 shares of the biotechnology company’s stock after buying an additional 786 shares during the period. US Bancorp DE’s holdings in Exelixis were worth $1,184,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of EXEL. Natixis Advisors L.P. purchased a new stake in shares of Exelixis in the 1st quarter worth approximately $325,000. BlackRock Inc. lifted its position in shares of Exelixis by 1.9% in the 1st quarter. BlackRock Inc. now owns 32,884,561 shares of the biotechnology company’s stock worth $745,493,000 after purchasing an additional 607,183 shares during the period. Great West Life Assurance Co. Can lifted its position in shares of Exelixis by 7.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 171,286 shares of the biotechnology company’s stock worth $3,990,000 after purchasing an additional 11,941 shares during the period. Yousif Capital Management LLC lifted its position in shares of Exelixis by 1.2% in the 1st quarter. Yousif Capital Management LLC now owns 166,497 shares of the biotechnology company’s stock worth $3,774,000 after purchasing an additional 1,931 shares during the period. Finally, LSV Asset Management purchased a new stake in shares of Exelixis in the 1st quarter worth approximately $12,872,000. Hedge funds and other institutional investors own 84.74% of the company’s stock.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several research reports. StockNews.com initiated coverage on shares of Exelixis in a research report on Wednesday, October 12th. They issued a “buy” rating for the company. JMP Securities reduced their price objective on shares of Exelixis from $26.00 to $25.00 and set a “market outperform” rating for the company in a research note on Friday, December 9th. Cowen reduced their price objective on shares of Exelixis from $26.00 to $21.00 in a research note on Wednesday, November 2nd. Royal Bank of Canada reduced their price objective on shares of Exelixis from $31.00 to $29.00 and set an “outperform” rating for the company in a research note on Wednesday, November 2nd. Finally, Truist Financial reduced their price objective on shares of Exelixis from $35.00 to $32.00 in a research note on Friday, December 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.55.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director George Poste sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 29th. The shares were sold at an average price of $16.68, for a total transaction of $667,200.00. Following the transaction, the director now owns 193,189 shares in the company, valued at approximately $3,222,392.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director George Poste sold 40,000 shares of the stock in a transaction on Tuesday, November 29th. The shares were sold at an average price of $16.68, for a total value of $667,200.00. Following the sale, the director now owns 193,189 shares in the company, valued at $3,222,392.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Peter Lamb sold 20,000 shares of the stock in a transaction on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $317,600.00. Following the completion of the sale, the executive vice president now owns 410,958 shares in the company, valued at approximately $6,526,013.04. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.

Exelixis Trading Down 0.7 %

Shares of Exelixis stock opened at $16.32 on Wednesday. Exelixis, Inc. has a 12-month low of $14.87 and a 12-month high of $23.40. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of 17.18, a PEG ratio of 0.55 and a beta of 0.69. The firm’s 50 day simple moving average is $16.46 and its two-hundred day simple moving average is $17.71.

Exelixis (NASDAQ:EXEL – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.05. Exelixis had a net margin of 18.78% and a return on equity of 13.11%. The business had revenue of $411.74 million for the quarter, compared to analyst estimates of $404.15 million. On average, sell-side analysts predict that Exelixis, Inc. will post 0.53 EPS for the current fiscal year.

About Exelixis

(Get Rating)

Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.